SG/PUT/VERTEX PHARMACEUTICALS/400/0.1/17.01.25

SG/PUT/VERTEX PHARMACEUTICALS/400/0.1/17.01.25 Stock

DE000SY01C80

Market Closed - Bid/Ask 02:32:53 2024-07-03 EDT			After market 14:13:06
0.98 ^EUR	-10.91%		1.04	+6.12%

Current month	+6.80%
1 month	-38.55%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart SG/PUT/VERTEX PHARMACEUTICALS/400/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
24-07-03	0.98	-10.91%
24-07-02	1.1	+1.85%
24-07-01	1.08	+4.85%
24-06-28	1.03	0.00%
24-06-27	1.03	0.00%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 02:32 am

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Société Générale
WKN	SY01C8
ISIN	DE000SY01C80
Date issued	2024-05-29
Strike	400 $
Maturity	2025-01-17 (198 Days)
Parity	10 : 1
Emission price	1.47 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.89 €
Lowest since issue	0.98 €
Delta	-0.17x
Omega	7.187
Premium	17.35x
Gearing	41.53x
Moneyness	0.8506
Difference Strike	-70.28 $
Difference Strike %	-17.57%
Spread	0.08 €
Spread %	7.34%
Theoretical value	1.040
Implied Volatility	31.37 %
Total Loss Probability	76.25 %
Intrinsic value	0.000000
Present value	1.040
Break even	388.79 €
Theta	-0.04x
Vega	0.08x
Rho	-0.05x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

473.8 USD

Average target price

468.3 USD

Spread / Average Target

-1.16%

Consensus